Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 541-549

  Gramatté, Thomas ^a,b   Oertel, Reinhard ^a   Terhaag, Bernd ^a,c   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTESTINE SECRETION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SMALL INTESTINE; VOLUNTEER;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; INTUBATION, GASTROINTESTINAL; MALE; PERFUSION; PROPANOLAMINES;

EID: 0029999340     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90182-4     Document Type: Article

References (27)

1. Haustein KO, Fiehring H, Oltmanns G, Femmer K. On the clinical pharmacology of talinolol, a new beta 1-adrenoceptor blocking agent. Int J Clin Pharmacol Biopharm 1979;17:465-70.
2. 1-adrenoceptor selectivity in man [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1994;349:R143.
3. le Petit G. Die pH-abhängige Lipoidlöslichkeit bei Arzneimittelgruppen. Pharmazie 1985;40:797-8.
4. 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995;16:403-14.
5. Oertel R, Richter K, Trausch B, Berndt A, Gramatté T, Kirch W. Elucidation of the structure of talinolol metabolites in man: determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatogr 1994;660:353-63.
6. Cooper H, Levitan R, Fordtran JS, Ingelfinger FJ. A method for studying absorption of water and solute from the human small intestine. Gastroenterology 1966;50:1-7.
7. Gramatté T, El Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 1994;46:253-9.
8. Gramatté T, Richter K. Paracetamol absorption from different sites in the human small intestine. Br J Clin Pharmacol 1994;37:608-11.
9. Gramatté T. Griseofulvin absorption from different parts in the human small intestine. Biopharm Drug Dispos 1994;15:747-59.
10. Fordtran JS, Rector FC, Ewton MF, Soter N, Kinney J. Permeability characteristics of the human small intestine. J Clin Invest 1965;44:1935-44.
11. Modigliani R, Rambaud JC, Bernier JJ. The method of intraluminal perfusion of the human small intestine; I: principle and technique. Digestion 1973;9:176-92.
12. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: University Press, 1980:334-64.
13. Malawer SJ, Powell DW. An improved turbidimetric analysis of polyethylene glycol utilizing an emulsifier. Gastroenterology 1967;53:250-6.
14. Scholtan W. Bestimmungsmethoden und Gesetzmässigkeiten der Serumproteinbindung von Arzneimitteln. Arzneimittelforschung 1978;28:1037-47.
15. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
16. Goebell H, Klotz U, Nehlsen B, Layer P. Oroileal transit of slow release 5-aminosalicylic acid. Gut 1993; 34:669-75.
17. Taylor DC. Sites and mechanisms of intestinal drug absorption. Pharm Int 1986;7:179-83.
18. Vidon N, Evard D, Godbillon J, et al. Investigation of drug absorption from the gastrointestinal tract of man; II: metoprolol in the jejunum and ileum. Br J Clin Pharmacol 1985;19(suppl):107S-12S.
19. Godbillon J, Evard D, Vidon N, et al. Investigation of drug absorption from the gastrointestinal tract of man; III: metoprolol in the colon. Br J Clin Pharmacol 1985;19(suppl):113S-8S.
20. Terhaag B, Sahre H, Lange U, Richter K, Feller K. Zum Einfluss der Nahrung auf die Absorption von Talinolol (Cordanum) am gesunden Probanden. Z Klin Med 1991;46:1021-3.
21. Ochsenfahrt H, Winne D. The contribution of solvent drag to the intestinal absorption of the basic drugs amidopyrine and antipyrine from the jejunum of the rat. Naunyn Schmiedebergs Arch Pharmacol 1974; 281:175-96.
22. George CF, Gruchy BS. Elimination of drugs by active intestinal transport. J Pharm Pharmacol 1979;31:643-4.
23. Lennernäs H, Regårdh CG. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm Res 1993;10:727-31.
24. Kuo SM, Whitby BR, Artursson P, Ziemniak JA. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm Res 1994; 11:648-53.
25. Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 1993;110:1009-16.
26. Wetterich U, Mutschler E, Spahn-Langguth H, Langguth P. Evidence for intestinal secretion of the β-adrenoceptor antagonist talinolol: data from humans and studies with Caco-2 cells [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1995;351(suppl): R1.
27. Wetterich U, Spahn-Langguth H, de Mey C, et al. Pharmacokinetics of talinolol enantiomers after oral racemate dosage [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1994;349(suppl):R150.